These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10933655)

  • 21. Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009-2018.
    Choat J; Young J; Petersen JM; Dietrich EA
    Clin Infect Dis; 2024 Jan; 78(Suppl 1):S4-S6. PubMed ID: 38294116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sensitivity spectrum of Francisella tularensis to antibiotics and synthetic antibacterial drugs].
    Vasi'lev NT; Oborin VA; Vasi'lev PG; Glushkova OV; Kravets ID; Levchuk BA
    Antibiot Khimioter; 1989 Sep; 34(9):662-5. PubMed ID: 2610533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis.
    Sutera V; Caspar Y; Boisset S; Maurin M
    Front Cell Infect Microbiol; 2014; 4():36. PubMed ID: 24672776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Septic pneumonic tularaemia caused by Francisella tularensis subsp. holarctica biovar II.
    Fritzsch J; Splettstoesser WD
    J Med Microbiol; 2010 Sep; 59(Pt 9):1123-1125. PubMed ID: 20522628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New therapeutic approaches for treatment of tularaemia: a review.
    Boisset S; Caspar Y; Sutera V; Maurin M
    Front Cell Infect Microbiol; 2014; 4():40. PubMed ID: 24734221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain.
    Aperis G; Fuchs BB; Anderson CA; Warner JE; Calderwood SB; Mylonakis E
    Microbes Infect; 2007 May; 9(6):729-34. PubMed ID: 17400503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin.
    Syrjälä H; Schildt R; Räisäinen S
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):68-70. PubMed ID: 1864276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Detection of persistent resistance to antibacterial drugs in various strains of Francisella tularensis].
    Pavlovich NV; Tynkevich NK; Ryzhko IV; Danilevskaia GI
    Antibiot Khimioter; 1992 Oct; 37(10):29-31. PubMed ID: 1296530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciprofloxacin for treatment of tularemia in children.
    Johansson A; Berglund L; Gothefors L; Sjöstedt A; Tärnvik A
    Pediatr Infect Dis J; 2000 May; 19(5):449-53. PubMed ID: 10819342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sensitivity of the causative agent of tularemia to antibiotics].
    Kudelina RI
    Antibiotiki; 1978 Aug; 23(8):710-4. PubMed ID: 686695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of 71 French isolates of Francisella tularensis subsp. holarctica to eight antibiotics and accuracy of the Etest method.
    Valade E; Vaissaire J; Mérens A; Hernandez E; Gros C; Le Doujet C; Paucod JC; Thibault FM; Durand B; Lapalus M; Dupuis I; Caclard A; Vidal DR; Cavallo JD
    J Antimicrob Chemother; 2008 Jul; 62(1):208-10. PubMed ID: 18397924
    [No Abstract]   [Full Text] [Related]  

  • 32. Discovery of D8-03 as an Inhibitor of Intracellular Growth of
    Whiles S; Zhang Q; Chamberlain Z; Singh MK; Steele S; Zheng L; Rosche K; Huang W; Gao H; Zhang Q; Kawula T
    ACS Infect Dis; 2024 Aug; 10(8):2775-2784. PubMed ID: 38876983
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparative characteristics of biological properties of Francisella tularensis strains isolated in the USSR].
    Pavlovich NV; Mishan'kin BN; Tynkevich NK; Ryzhko IV; Romanova LV; Danilevskaia GI
    Antibiot Khimioter; 1991 Oct; 36(10):23-5. PubMed ID: 1805689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Streptomycin and alternative agents for the treatment of tularemia: review of the literature.
    Enderlin G; Morales L; Jacobs RF; Cross JT
    Clin Infect Dis; 1994 Jul; 19(1):42-7. PubMed ID: 7948556
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Heine HS; Miller L; Halasohoris S; Purcell BK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674048
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pleiotropic nature of mutation of resistance to 2,3,5-triphenyl- tetrazolium chloride of Francisella tularensis].
    Pavlovich NV; Danilevskaia GI; Khodova VA; Ryzhko IV; Mishan'kin BN
    Antibiot Khimioter; 1992 Apr; 37(4):28-31. PubMed ID: 1417312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tularemia: treatment failures with outpatient use of ceftriaxone.
    Cross JT; Jacobs RF
    Clin Infect Dis; 1993 Dec; 17(6):976-80. PubMed ID: 8110955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolation of Francisella tularensis biovar palaearctica from human blood.
    Tärnvik A; Henning C; Falsen E; Sandström G
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):146-50. PubMed ID: 2498098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Francisella tularensis as a potential agent of bioterrorism?
    Maurin M
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):141-4. PubMed ID: 25413334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of the Turkish isolates of Francisella tularensis.
    Gurcan S; Karabay O; Karadenizli A; Karagol C; Kantardjiev T; Ivanov IN
    Jpn J Infect Dis; 2008 May; 61(3):223-5. PubMed ID: 18503176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.